Abstract
On average, adults who smoke cigarettes weigh less than nonsmokers. However, they have a greater tendency towards abdominal obesity, and, when they stop smoking, about 80% of them gain weight. Whereas original estimates of the amount of weight ex-smokers gain in one-years time was about five pounds, long-term follow-up of sustained quitters suggests that the weight gain may be considerably greater. While the health benefits of quitting smoking outweigh the adverse health consequences of post-cessation weight gain, studies on the effects of smoking cessation on lung function show that the weight gained by quitters may significantly reduce the beneficial effects of smoking cessation on lung function. Prevention of post-cessation weight gain has proved to be an elusive target. However, studies show that life style changes, diet, exercise, and pharamacotherapy, alone and in combination, may reduce post-cessation weight gain, at least for the period of time that the treatments are in effect. Nicotine replacement therapy, bupropion SR, and, to a lesser extent, varenicline, are the most effective pharmacological deterrents to post-cessation weight gain, although the latter medication may yield the best quit smoking results. Research on pharmacogenetics and other medications may increase physicians armamentarium in the future.
Current Respiratory Medicine Reviews
Title: Smoking and Weight
Volume: 4 Issue: 2
Author(s): Norman Hymowitz
Affiliation:
Abstract: On average, adults who smoke cigarettes weigh less than nonsmokers. However, they have a greater tendency towards abdominal obesity, and, when they stop smoking, about 80% of them gain weight. Whereas original estimates of the amount of weight ex-smokers gain in one-years time was about five pounds, long-term follow-up of sustained quitters suggests that the weight gain may be considerably greater. While the health benefits of quitting smoking outweigh the adverse health consequences of post-cessation weight gain, studies on the effects of smoking cessation on lung function show that the weight gained by quitters may significantly reduce the beneficial effects of smoking cessation on lung function. Prevention of post-cessation weight gain has proved to be an elusive target. However, studies show that life style changes, diet, exercise, and pharamacotherapy, alone and in combination, may reduce post-cessation weight gain, at least for the period of time that the treatments are in effect. Nicotine replacement therapy, bupropion SR, and, to a lesser extent, varenicline, are the most effective pharmacological deterrents to post-cessation weight gain, although the latter medication may yield the best quit smoking results. Research on pharmacogenetics and other medications may increase physicians armamentarium in the future.
Export Options
About this article
Cite this article as:
Hymowitz Norman, Smoking and Weight, Current Respiratory Medicine Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339808784222830
DOI https://dx.doi.org/10.2174/157339808784222830 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook
Current Drug Delivery Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review
Reviews on Recent Clinical Trials Editorial (Hot Topic: Cardiovascular Disease Biomarkers: from Tradition to Modernity)
Current Topics in Medicinal Chemistry Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease
Current Vascular Pharmacology Synthesis and Biological Evaluation of Ezetimibe Analogs as Possible Cholesterol Absorption Inhibitors
Letters in Drug Design & Discovery Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?
Current Vascular Pharmacology Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology